A Phase 1/2a Study of the 2S,4R Enantiomer of Ketoconazole in Subjects With Type 2 Diabetes Mellitus

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 28, 2005

Study Completion Date

August 31, 2006

Conditions
Type 2 Diabetes
Interventions
DRUG

2S, 4R Ketoconazole (DIO-902)

Trial Locations (5)

20003

Asha Thomas, MD - Medstar, Washington D.C.

68131

Marc Rendell, MD - Creighton University, Omaha

75247

Carlos Arauz-Pacheco, MD - Radiant Research, Dallas

78229

Sherwin Schwartz, MD - Diabetes and Glandular Disease Clinic, San Antonio

97239

Dr. Andrew Ahmann, MD - Radiant Research, Portland

Sponsors

Lead Sponsor

All Listed Sponsors
lead

DiObex

INDUSTRY